Nazis demanded to know if ‘The Hobbit’ author was Jewish. He responded with a high-class burn.
I love Tolkien for this classy reply ! https://t.co/hKgODzxf70
@WhatsApp
how does one get actual help from your help center please? If locked out of whats app and NOT receiving a code or call . Have sent request for help , tried numerous times to request code or call. Locked out for over 18 hours.
Unpublished topline data from SELECT indicates that in non-diabetic overweight patients, wt loss with a GLP-1 agonist is more than cosmetic & reduces the risk of death/stroke & heart attack by 20%.
Time to treat obesity like the complex disease it is rather than a moral failing.
1/ 📣 New from my team in @NatureMedicine
In a study of 6 million people, we examined risk trajectories of 80 components of Long Covid over 2 years post-infection
📌 Risks remained elevated for many Long Covid conditions even 2 years infection
A 🧵
https://t.co/v20GUhKvDj
This article is one of the more important things I've written.
It's about nutrition misinformation.
▶️What it is
▶️How widespread it is
▶️Where it comes from
▶️Why people believe it
▶️How, and how much, it harms us
https://t.co/b36jXtRXco
Novo Nordisk reports that semaglutide 2.4 mg reduced cardiovascular events by 20% in ppl with obesity in the SELECT trial.
Context: This is the third RCT to show CV event reduction with sema.
https://t.co/1gvqimJ3Hm
https://t.co/oTQfAhNe79
https://t.co/dLsjoqY7Ns
Unpublished topline data from SELECT indicates that in non-diabetic overweight patients, wt loss with a GLP-1 agonist is more than cosmetic & reduces the risk of death/stroke & heart attack by 20%.
Time to treat obesity like the complex disease it is rather than a moral failing.
We haven’t yet seen the actual data but a 20% reduction of cardiovascular events in a 17, 500 participant randomized trial of a GLP-1 anti-obesity drug is a big deal and likely will change the reimbursement landscape (and further promote uptake)
🚨BREAKING: Semaglutide meets primary end-point in SELECT trial—reduces 3-point composite MACE by 20%.
All endpoints (CV death, non-fatal MI, non-fatal stroke) supposedly contribute to the demonstration of superiority vs. Placebo.
“Benn’s out-of-the-box thinking, accessibility to patients, and transparency in the way she worked irked senior male managers and doctors. “. Says it all . Top breast cancer surgeon quits Helen Joseph Hospital,... https://t.co/FIv1vyJbFI